SEC Form 4 · accession 0001140361-17-034179
Spyre Therapeutics, Inc. · SYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anthony G. Quinn
Officer — Interim CEO · Director
Period of report
Aug 31, 2017
Accepted (ET)
Sep 1, 2017 · 5:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636282
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $4.11 | Aug 31, 2017 | A | 150,000 | A | — | Aug 30, 2027 | Common Stock | 150,000 | 150,000 | D |
Explanation of responses
- F1The stock option vests and becomes exercisable as to 100% of the shares subject to the option on July 18, 2018, subject to the continuing service of the Reporting Person on the vesting date.